The human microbiome is a collection of microorganisms found on and within the human body. It contains various organisms, including bacteriophages, bacteria, fungi, viruses, and protozoa. The microbiota might weigh up to five pounds and help control our immune system, digest our food, defend against other disease-causing bacteria, and generate vitamins such as B and Vitamin K. The human microbiome is a market with immense potential, including bacteria, archaea, viruses, and eukaryotes inside and outside our bodies. The demand for prebiotics and probiotics is expected to grow significantly due to increased awareness about their role in preventive health measures. Factors driving this growth include the rising geriatric population, the growing prevalence of lifestyle diseases, and government funding for initiatives like the 'Human Microbiome Project' and 'the Earth Microbiome.' These initiatives provide opportunities for market players to research and develop new products, driving market growth during the forecast period.
The human microbiome is a significant area of study and has the potential to revolutionize healthcare. It is related to the rise of lifestyle-related diseases and the aging population, and it directly affects conditions such as diabetes. The International Diabetes Federation 2021 statistics show that there are 52.7 million people aged 20-79 years in Europe with diabetes, which is expected to reach 69 million by 2045. The diversity of gut microbes, particularly the presence of butyrate-producing bacteria, has a significant impact on insulin resistance and the risk of type 2 diabetes, demonstrating the influence of the human microbiome on health. This rise in lifestyle-related illnesses, such as diabetes, will fuel market growth during the upcoming years.
Persephone Biosciences Inc. is developing immune-boosting microbiome therapeutics to prevent and treat COVID-19. They also work on a stool-based diagnostic test to identify patients at risk for severe complications. The pandemic has increased awareness of microbiota therapies and diagnosis, leading to a growing market for these solutions.
Seres Therapeutics Inc. and Nestlé Health Science collaborated to jointly commercialize an investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection in Canada and the United States. This collaboration aims to boost market segment growth and strengthen the position of the market players, potentially leading to a new treatment modality.
North American Human Microbiome Market
The United States is the largest market in North America for the human microbiome, followed by Canada. The American Cancer Society predicts that there will be approximately 1,918,030 new cancer diagnoses in the United States in 2022. According to Globocan 2020 data, there are 274,364 new cancer instances, which is expected to reach 400,564 by 2040. The rising incidence of cancer is expected to drive market expansion due to the role of gut microbiota in regulating tumor therapy and improving patients' response to immunotherapy while reducing the adverse effects of chemotherapeutic drugs. This market expansion is further supported by an increasing number of research studies and the backing of regulatory bodies for investigation. 4D Pharma plc received FDA approval in February 2022 for two Live Biotherapeutics, MRx0005 and MRx0029, as investigational new drugs (IND) to treat Parkinson's disease. These approvals are expected to impact the market's development positively.Human Microbiome Company Analysis
Prominent players in the Global Human Microbiome Market include DuPont, Evelo Biosciences Inc., Finch Therapeutics Group Inc., Ginkgo Bioworks, Seres Therapeutics, AOBiome, Astarte Medical, Axial Biotherapeutics, Inc. and Osel Inc.Human Microbiome Company News
Sept 2022: The FDA has completed the BLA application process for Seres Therapeutics Inc.'s SER-109 drug, a groundbreaking approach to treating recurrent C. difficile infection. This innovative treatment aims to elevate the current standard of care for rCDI.Sept 2022: The FDA's Vaccines and Related Biological Products Advisory Committee approved Ferring Pharmaceuticals' RBX2660 investigational microbiota-based live biotherapeutic trial to reduce C. difficile infection (CDI) recurrence after antibiotic therapy.
September 2022: Seres Therapeutics Inc. completed the submission process for its BLA application to the FDA for SER-109 to prevent recurrent C. difficile infection (rCDI). It is an entirely new treatment modality that promises to improve the current standard of medical care for rCDI.
September 2022: Ferring Pharmaceuticals received a positive vote for RBX2660 by the FDA's Vaccines and Related Biological Products Advisory Committee for its investigational microbiota-based live biotherapeutic study, which has the potential to reduce the recurrence of C. difficile infection (CDI) after antibiotic treatment.
Application - Global Human Microbiome Market breakup into 2 Viewpoints
1. Therapeutics2. Diagnostics
Disease - Global Human Microbiome Market breakup into 7 Viewpoints
1. Obesity2. Diabetes
3. Autoimmune Disorders
4. Cancer
5. Gastrointestinal Disorders
6. Central Nervous System Disorders
7. Other Diseases
Product - Global Human Microbiome Market breakup into 4 Viewpoints
1. Probiotics2. Prebiotics
3. Symboitics
4. Other Products
Geography - Global Human Microbiome breakup of 25 Countries
North America
1. United States2. Canada
Europe
1. France2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey
Asia Pacific
1. China2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand
Latin America
1. Brazil2. Mexico
3. Argentina
Middle East & Africa
1. South Africa2. Saudi Arabia
3. United Arab Emirates
All the Key players have been covered from 4 Viewpoints:
1. Overviews2. Recent Developments
3. Product Portfolio
4. Revenue
Companies List
1. DuPont2. Evelo Biosciences Inc.
3. Finch Therapeutics Group Inc.
4. Ginkgo Bioworks
5. Seres Therapeutics
6. AOBiome
7. Astarte Medical
8. Axial Biotherapeutics
Table of Contents
Companies Mentioned
- DuPont
- Evelo Biosciences Inc.
- Finch Therapeutics Group Inc.
- Ginkgo Bioworks
- Seres Therapeutics
- AOBiome
- Astarte Medical
- Axial Biotherapeutics Inc.
- Osel Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | June 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 0.72 Billion |
| Forecasted Market Value ( USD | $ 3.05 Billion |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
